PEX010 PEX020 PEX030

Filament are planning a Phase I studies exploring its three proprietary botanical psychedelics; PEX010 (oral psilocybin), PEX020 (oral psilocin), and PEX030 (sublingual psilocin), in healthy subjects.

This Phase I trial is led by the Translational Psychedelic Research Program (TrPR) at the University of California San Francisco (UCSF).

The trial is set to begin in 2022.

Topic Healthy Subjects
Compound Psilocybin
Country Canada
Visit trial
Status Planned
Results Published
Start date 02 January 2022
End date 02 January 2023
Chance of happening 60%
Phase Phase I
Design Open
Type Interventional
Generation Second
Participants 20
Sex All
Age 18- 99
Therapy No

Trial Details



NCT Number

Sponsors & Collaborators

Filament Health
Filament Health is a global extraction and drug discovery company. The company have a deep natural psychedelics IP portfolio and are led by an accomplished botanical extraction management team.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.